Volition's goal is to make its non-invasive cancer blood tests as common and simple to use as existing diabetic and cholesterol tests on similar formats.


Volition’s HyperGenomics® technology aims to determine specific epigenetic signatures from cancer biopsies. HyperGenomics® aims to be used as a second line once disease has been diagnosed, to accurately determine the specific subtype of disease and to help decide the most appropriate therapy.

Selecting the correct treatment approach can significantly improve outcome, reduce side effects and deliver cost savings to payers, in many diseases including cancer. There is an increasing shift to a more personalized medicine approach as there are many different types of cancer that can affect the same organ, each of which require different treatments and drugs.

HyperGenomics® is available under licence from Volition. If you are interested in partnering with Volition please contact Mark Eccleston, Chief Scientific Officer for HyperGenomics, at This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Copyright © 2011 VolitionRX. All Rights Reserved
VolitionRx - Singapore - 1 Scotts Road - #24-05 Shaw Centre - Singapore 228208
VolitionRx - Belgium - Centre Technologique - Rue du Séminaire, 20A - B-5000 Namur - Belgium